CN112386547B - 菠萝萃取物的皮肤保健用途 - Google Patents
菠萝萃取物的皮肤保健用途 Download PDFInfo
- Publication number
- CN112386547B CN112386547B CN201911411765.3A CN201911411765A CN112386547B CN 112386547 B CN112386547 B CN 112386547B CN 201911411765 A CN201911411765 A CN 201911411765A CN 112386547 B CN112386547 B CN 112386547B
- Authority
- CN
- China
- Prior art keywords
- skin
- cells
- pineapple
- extract
- pineapple peel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940013712 pineapple extract Drugs 0.000 title claims abstract description 16
- 230000036559 skin health Effects 0.000 title abstract description 4
- 239000011148 porous material Substances 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 230000001965 increasing effect Effects 0.000 claims abstract description 15
- 239000002932 luster Substances 0.000 claims abstract description 12
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 10
- 241000234671 Ananas Species 0.000 claims description 71
- 235000007119 Ananas comosus Nutrition 0.000 claims description 71
- 239000002904 solvent Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 230000003061 melanogenesis Effects 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 73
- 210000003491 skin Anatomy 0.000 abstract description 63
- 230000000694 effects Effects 0.000 abstract description 27
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 18
- 230000003078 antioxidant effect Effects 0.000 abstract description 15
- 239000000203 mixture Substances 0.000 abstract description 15
- 239000003963 antioxidant agent Substances 0.000 abstract description 14
- 210000004927 skin cell Anatomy 0.000 abstract description 8
- 230000004792 oxidative damage Effects 0.000 abstract description 6
- 239000000419 plant extract Substances 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 56
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 44
- 102000005720 Glutathione transferase Human genes 0.000 description 23
- 108010070675 Glutathione transferase Proteins 0.000 description 23
- 239000002609 medium Substances 0.000 description 23
- 229960003180 glutathione Drugs 0.000 description 22
- 239000000243 solution Substances 0.000 description 19
- 238000011282 treatment Methods 0.000 description 17
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 239000006143 cell culture medium Substances 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 108010024636 Glutathione Proteins 0.000 description 9
- 230000002500 effect on skin Effects 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 230000036564 melanin content Effects 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 210000001626 skin fibroblast Anatomy 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000010631 GST assay Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241001244920 Eucomis bicolor Species 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003718 aged appearance Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- -1 elixir (elixir) Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D13/00—Finished or partly finished bakery products
- A21D13/06—Products with modified nutritive value, e.g. with modified starch content
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及植物提取物领域,尤其是关于菠萝萃取物的皮肤保健用途。本发明提供一种菠萝萃取物用于制备在皮肤抑制黑色素生成、增加含水量、提升光泽、及减少毛孔的医药组合物的用途,亦提供一种菠萝萃取物用于制备提升细胞抗氧化力的医药组合物的用途。所述菠萝萃取物具有抑制黑色素生成及改善肤质的功效,包括提升皮肤含水量与光泽及减少毛孔,亦能提升包含皮肤细胞的多种细胞的抗氧化力,藉此减少个体或皮肤的氧化伤害。
Description
技术领域
本发明涉及植物提取物领域,尤其是关于菠萝萃取物的皮肤保健用途。
背景技术
皮肤是人体隔绝外界环境中的刺激,例如紫外线、病原体、摩擦力等,与防止水分流失的首要防线。皮肤具有表皮层、真皮层、及皮下组织的三层结构。表皮是皮肤的最外层并且不断更新。表皮与真皮间存在持续分裂的细胞,例如纤维母细胞、角质细胞、黑色素细胞。真皮层富含胶原蛋白、弹性蛋白、及吸水力强的玻尿酸,其赋予肌肤弹性和支撑力量。由于年龄增长及环境刺激,皮肤会出现斑点、肤色黯沉、皱纹、松弛、凹陷、及毛孔粗大等老化外观,并且累积氧化伤害。为了推迟皮肤老化,抑制黑色素过度生成、增加皮肤含水量及提升皮肤抗氧化力极为重要。
习知用以改善皮肤老化外观的方法包括对皮肤施用抑制黑色素生成的化合物,及注射胶原蛋白或玻尿酸至真皮层。然而,部分抑制黑色素生成的化合物可能导致皮肤过敏,例如曲酸(kojic acid)。此外,注射至皮肤的胶原蛋白或玻尿酸易随时间被体内酵素分解,导致必须定期施打该些物质,成本高昂。
此外,习知提升皮肤抗氧化力的方法主要是直接使用抗氧化剂于皮肤。该些抗氧化剂虽能协助清除造成皮肤细胞损伤的自由基,但无法透过改变细胞生理条件而提升皮肤细胞本身的抗氧化力。
有鉴于此,开发一种兼具皮肤美白、增加皮肤含水量、及提升细胞抗氧化力的组合物以制备新型态的护肤产品,实有其必要。
发明内容
发明的一目的在提供一种菠萝萃取物用于制备在皮肤抑制黑色素生成、增加含水量、提升光泽、及减少毛孔的医药组合物的用途,其中该菠萝萃取物是以一溶剂萃取一菠萝果皮而获得。
在本发明的一实施例中,该溶剂与该菠萝果皮的重量比范围为20:1至1:1,较佳为10:1至1:1。
在本发明的一实施例中,该溶剂为水,且该萃取是在50℃至100℃进行,较佳为65℃至85℃。
本发明的另一目的在提供一种前述菠萝萃取物用于制备提升细胞抗氧化力的医药组合物的用途。
在本发明的一实施例中,该菠萝萃取物增加该细胞内谷胱甘肽(glutathione,简称GSH)的含量,或增加该细胞的谷胱甘肽S转移酶(glutathione S-transferase,简称GST)活性。
本发明揭露菠萝萃取物具有抑制黑色素生成及改善肤质的功效,包括提升皮肤含水量与光泽及减少毛孔。该菠萝萃取物亦能提升包含皮肤细胞的多种细胞的抗氧化力,藉此减少个体或皮肤的氧化伤害。因此,该菠萝萃取物可用于制备在皮肤抑制黑色素生成、增加含水量、提升光泽、及减少毛孔的组合物,或制备提升细胞抗氧化力的组合物。该组合物可具有粉末、颗粒、溶液、胶体或膏体的形式,且可制成医药品、食品、饮品、或营养补充剂,藉由口服、局部施用于皮肤或其他方式给予一个体。
以下将配合图式进一步说明本发明的实施方式,下述所列举的实施例是用以阐明本发明的特点及应用,而非用以限定本发明的范围,任何熟习此技艺者,在不脱离本发明的精神和范围内,当可做些许更动与润饰,因此本发明的保护范围当视后附的申请专利范围所界定者为准。
附图说明
图1是皮肤纤维母细胞以本发明一实施例的菠萝果皮萃取物处理后的谷胱甘肽相对含量图;
图2是肝癌细胞株以本发明一实施例的菠萝果皮萃取物处理后的谷胱甘肽相对含量图;
图3是皮肤纤维母细胞以本发明一实施例的菠萝果皮萃取物处理后的谷胱甘肽S转移酶活性图。
图4是外周血单核细胞以本发明一实施例的菠萝果皮萃取物处理后的谷胱甘肽S转移酶活性图;
图5是本发明一实施例的菠萝果皮萃取物对过氧化氢(H2O2)刺激下皮肤纤维母细胞活性氧物质生成的抑制作用图;
图6是黑色素瘤细胞以本发明一实施例的菠萝果皮萃取物处理后的黑色素相对含量图;
图7是受试者施用一含1%菠萝果皮萃取物的面膜组合物或一基底精华液的前或施用15分钟后的皮肤含水量图;
图8是受试者施用一含1%菠萝果皮萃取物的面膜组合物或一基底精华液的前或施用15分钟后的皮肤光泽度图;
图9是受试者施用一含1%菠萝果皮萃取物的面膜组合物或一基底精华液的前或15分钟后的皮肤毛孔数量图。
具体实施方式
定义
除非另有说明,本文中所使用的「一」、「该」及类似用语应理解为包含单数及复数形式。
本文中所使用数值为近似值,所有实验数据皆表示在20%的范围内,较佳为在10%的范围内,最佳为在5%的范围内。
本文所述的医药组合物可利用熟习此技艺者所详知的技术而制备成一适合于非经肠地道(parenterally)或口服地(orally)施用的剂型(dosage form),其包括但不限于:注射品(injection)[例如,无菌的水性溶液(sterile aqueous solution)或分散液(dispersion)]、粉末(sterile powder)、锭剂(tablet)、片剂(troche)、口含锭(lozenge)、丸剂(pill)、胶囊(capsule)、分散性粉末(dispersible powder)、细颗粒(granule)、溶液、悬浮液(suspension)、乳剂(emulsion)、糖浆(syrup)、酏剂(elixir)、浓浆(slurry)以及类似物。
本文所述的医药组合物可由非经肠道途径(parenteral routes)施用,其包括但不限于:透皮(transdermal)施用、腹膜内注射(intraperitoneal injection)、皮下注射(subcutaneous injection)、肌肉内注射(intramuscular injection)、及静脉内注射(intravenous injection)。
本文所述的医药组合物可包含一广泛使用于药物制造技术的医药上可接受的载剂(pharmaceutically acceptable carrier)。该医药上可接受的载剂可包含一或多种选自于由下列所构成的群组中的试剂:溶剂(solvent)、乳化剂(emulsifier)、悬浮剂(suspending agent)、分解剂(decomposer)、黏结剂(binding agent)、赋形剂(excipient)、安定剂(stabilizing agent)、螯合剂(chelating agent)、稀释剂(diluent)、胶凝剂(gelling agent)、防腐剂(preservative)、润滑剂(lubricant)、吸收延迟剂(absorption delaying agent)、脂质体(liposome)以及类似物。该些试剂的选用与数量落在熟习此项技术者的专业素养与例行技术范畴内。
前述医药上可接受的载剂包含有一选自于由下列所构成的群组中的溶剂:水、生理盐水(normal saline)、磷酸盐缓冲盐溶液(phosphate buffered saline,PBS)、含糖溶液、含醇水溶液(aqueous solution containing alcohol)、及它们的组合。
材料与方法
材料
自Thermo Fisher Scientific公司购买含Earle’s平衡盐溶液的Eagle’s最低基本培养基(Gibco Eagle’s minimum essential medium,MEM)、DMEM培养基(GibcoDulbecco’s modified Eagle’s medium)、胎牛血清(Gibco fetal bovine serum,FBS)、青霉素/链霉素(Gibco penicillin/streptomycin)、非必需胺基酸、碳酸氢钠、丙酮酸钠、及磷酸缓冲盐溶液(Gibco phosphate buffered saline,PBS)。自PEPROTECH公司购买人类巨噬细胞聚落刺激因子(macrophage colony stimulating factor,M-CSF)及人细胞核因子KB受体活化因子配体(receptor activator of nuclear factor kappaB ligand,RANKL)。自abcam公司购买谷胱甘肽检测试剂组(GSH Assay Kit ab112132)及谷胱甘肽S转移酶活性检测试剂组(GST Activity Assay Kit ab65326)。自ECHO Chemical公司购买二甲基亚砜(dimethyl sulfoxide,DMSO)。自Sigma公司购买过氧化氢(H2O2)及二氯二氢荧光素二乙酸酯(2,7-dichloro-dihydro-fluorescein diacetate,DCFH-DA)。该DCFH-DA使用前是溶于DMSO以配制为5mg/mL DCFH-DA溶液。
细胞培养
以下实施例所用细胞包括购自食品工业发展研究所生物资源保存及研究中心(Bioresource Collection and Research Center,BCRC)的人类皮肤纤维母细胞CCD-966SK(ATCC BCRC 60153),以及购自美国典型培养物保存中心(American Type CultureCollection,ATCC)的小鼠黑色素瘤细胞株B16F10(ATCC CRL-6475)、人类肝癌细胞株HepG2(ATCC HB-8065)、及人类外周血单核细胞(peripheral mononuclear mononuclear cell,PBMC)。CCD-966SK细胞在37℃、5%二氧化碳的条件下培养于添加10%FBS、1mM丙酮酸钠、1.5g/L碳酸氢钠、及0.1mM非必需胺基酸的MEM培养基,以下称MEM细胞培养基。PBMC细胞在37℃、5%二氧化碳的条件下培养于添加10%FBS、40ng/mL RANKL、25ng/mL M-CSF、1%青霉素/链霉素的MEM培养基,以下称蚀骨细胞分化培养基。B16F10细胞及HepG2细胞是在37℃、5%二氧化碳的条件下培养于添加10%FBS及1%青霉素/链霉素的DMEM培养基,以下称DMEM细胞培养基。
谷胱甘肽(GSH)含量的测定
细胞内GSH含量的测定是使用abcam的GSH检测试剂组。简言之,依据厂商使用说明,以PBS溶液清洗经过指定处理的细胞及再悬浮该细胞于1mL PBS溶液。其后,以巯基染剂(稀释1000倍)在37℃对该细胞染色15分钟。该染剂本是非荧光化合物,但与巯基反应后会发出绿色荧光。染色后,该细胞以PBS溶液清洗及再悬浮于200μL PBS溶液,再以流式细胞仪(flow cytometry;BD)侦测绿色荧光讯号(激发波长为490nm,侦测波长为520nm)。
谷胱甘肽S转移酶(GST)活性分析
细胞内GST活性的测定是使用abcam的GST活性检测试剂组。简言之,依据厂商使用说明,以PBS溶液清洗经过指定处理的细胞及再悬浮该细胞于150μL GST检测缓冲液(GSTassay buffer),藉由吸放(pipetting)该悬浮液数次以获得一细胞裂解液。其后,以离心方式(10000g,4℃,15分钟)收集该细胞裂解液的上清液。将50μL/孔的该上清液(实验组)、正控制组试剂、或GST检测缓冲液加入一96孔盘,并于各孔添加5μL GSH及50μL反应液(含1μLGST受质溶液及49μL GST检测缓冲液),所得混合液于室温反应并且每隔3分钟测量在340nm的吸光值(OD340),持续15分钟。最终,计算每分钟的OD340变化及进一步计算GST活性。
黑色素含量的测定
黑色素瘤细胞株B16F10的黑色素含量测定方法简述如下。自经过指定处理的细胞培养物中收集细胞。该细胞以PBS溶液清洗并以胰蛋白酶(trypsin)溶液处理3分钟,所得悬浮细胞以离心方式(400xg,5分钟)收集,经PBS溶液清洗二次,而后再悬浮于200μL PBS溶液。该细胞悬浮液以液态氮冷冻10分钟,再置于室温约30分钟至完全解冻后,以离心方式(12,000xg,3分钟)移除上清液。余下细胞沉淀与120μL的1N氢氧化钠水溶液混合均匀,再于60℃加热1小时以获得一含溶解黑色素的细胞裂解液。将100μL该细胞裂解液移入一96孔盘,并使用ELISA读盘机(enzyme-linked immunosorbent assay reader;BioTek)测量该细胞裂解液在450nm的吸光值(OD 450)。黑色素相对含量是依下列公式计算:
黑色素相对含量(%)=(各组OD450值/对照组OD450值)×100%。
皮肤含水量测试
皮肤含水量是利用多功能皮肤检测系统MPA 580(C+K electronic,德国)的含水量测定探头(CM825),藉由导电性变化测量待测区域的皮肤含水量。测试过程中,以Corneometer探头按压受试者的皮肤待测区域(避免同一点连续测量),进而得到皮肤含水量数值。由于环境的温度及湿度会影响皮肤含水量,受试者需要先进入恒温、恒湿的检测室平衡20分钟后才进行测试。测试的环境条件为温度20℃±1℃,相对湿度50%±10%,且避免空气扰动。
皮肤光泽度及毛孔数量分析
皮肤光泽度是利用多功能皮肤检测系统MPA 580(C+K electronic,德国)的光泽度测定探头(Glossymeter GL 200),通过照射到皮肤表面光线的直接反射和散射而得到皮肤光泽度数值。
皮肤毛孔数量是利用VISIA-CR全脸肤质检测仪(Canfield scientific,USA)的全光域波长及偏光波长的光源,于密闭的照相室内拍摄受试者的脸部,取得清晰图文件后,再以影像软件分析而得。
统计分析
数据表示为平均值±标准偏差(SD)。使用Excel软件进行统计分析,数据间在统计上的显着差异以学生t检验(student's t-test)判定。
实施例1
菠萝果皮萃取物的制备
本文所述的菠萝(Ananas comosus)果皮是指成熟菠萝果实的表面覆盖层。菠萝是一种热带水果,其果实是复数菠萝花的果实结合而成的单一复合果(multiple fruit)。未成熟的菠萝果实呈绿色,其在成熟后转为黄色。
为获得一菠萝果皮萃取物,自一菠萝果实取得果皮,并将该菠萝果皮洗净及破碎成小块。其后,以水、醇类、或醇水混合物为溶剂对菠萝果皮碎块进行萃取。醇类的例子包括甲醇、乙醇、正丙醇、异丙醇等低碳数的醇类。该溶剂与该菠萝果皮的重量比为20:1至1:1,较佳为10:1至5:1。萃取温度为介于50℃至100℃,较佳为75℃至95℃。以下实施例2-6所述菠萝果皮萃取物皆是依前述方法以水萃取菠萝果皮0.5至3小时而制得。
经上述萃取步骤所得菠萝果皮萃取物冷却至室温后,可进一步使用200至400目(mesh)的滤网过滤,以移除残余固体物。该过滤后的菠萝果皮萃取物可进一步在45℃至70℃进行减压浓缩而获得一浓缩产物。为获得固态的菠萝果皮萃取物,可将前述浓缩的菠萝果皮萃取物以例如冷冻干燥、喷雾干燥等干燥方式去除溶剂,因此获得干燥的菠萝果皮萃取物。
实施例2
菠萝果皮萃取物促进谷胱甘肽生成
为检视菠萝果皮萃取物对细胞内具抗氧化功效的谷胱甘肽(GSH)含量的影响,测定人类皮肤纤维母细胞CCD-966SK或人类肝癌细胞株HepG2以实施例1所述菠萝果皮萃取物处理后的GSH含量变化。简言之,将CCD-966SK细胞或HepG2细胞依2×105细胞/孔接种于6孔培养盘,各孔含有2mL MEM细胞培养基。在37℃隔夜培养细胞后,移除该培养基,再以含有0.3125mg/mL菠萝果皮萃取物的2mL MEM细胞培养基处理各孔细胞(实验组)。另设置对照组,是仅以2mL MEM细胞培养基处理CCD-966SK细胞或HepG2细胞。在37℃培养24小时后,收集前述各组细胞以巯基荧光染剂测定GSH含量。
图1显示皮肤纤维母细胞经不同处理后的GSH相对含量,其数值表示为相对于对照组的荧光讯号强度的倍数;图中***表示相比对照组为p<0.001。依据图1,相比对照组,菠萝果皮萃取物的处理显着提升皮肤纤维母细胞的GSH含量至约1.9倍,说明施用菠萝果皮萃取物能促进皮肤细胞内谷胱甘肽的生成,因此增加皮肤对氧化伤害的抵抗力,例如对紫外线伤害的抵抗力。
图2显示HepG2细胞经不同处理后的GSH相对含量;图中*表示相比对照组为p<0.05。依据该图,相比对照组,菠萝果皮萃取物的处理明显提升HepG2细胞的GSH含量至约1.4倍,说明施用菠萝果皮萃取物能提高肝细胞内谷胱甘肽的生成。
实施例3
菠萝果皮萃取物提高细胞的谷胱甘肽S转移酶活性
为检视菠萝果皮萃取物对细胞内负责清除有毒物质(如氧化压力所产生的活性氧物质)的谷胱甘肽S转移酶(GST)活性的影响,评估人类皮肤纤维母细胞CCD-966SK或外周血单核细胞(PBMC)以实施例1所述菠萝果皮萃取物处理后,其GST的总体活性变化。简言之,将CCD-966SK细胞或PBMC细胞依2×105细胞/孔接种于6孔培养盘,各孔含有2mL MEM细胞培养基。在37℃隔夜培养细胞后,移除该培养基,并以含有0.3125mg/mL或0.625mg/mL菠萝果皮萃取物的2mL MEM细胞培养基处理各孔细胞(实验组)。另设置对照组,是仅以3mL MEM细胞培养基处理CCD-966SK细胞或PBMC细胞。在37℃培养24小时后,收集前述各组细胞用于GST活性分析。
图3显示皮肤纤维母细胞经不同处理后的GST相对活性,其数值表示为相对于对照组的GST活性的倍数;图中*表示相比对照组为p<0.05。依据图3,相比对照组,菠萝果皮萃取物的处理显着提升皮肤纤维母细胞的GST活性至约1.06倍,说明施用菠萝果皮萃取物能增加皮肤细胞清除例如活性氧物质(ROS)的自由基的能力,因此有利于减少皮肤的氧化伤害,包括对脱氧核醣核酸(DNA)、蛋白质及脂质等细胞组成分子的损伤。
图4显示PBMC细胞经不同处理后的GST相对活性;图中***表示相比对照组为p<0.001。依据该图,相比对照组,菠萝果皮萃取物的处理显着提升PBMC细胞的GST活性至约1.48倍,说明施用菠萝果皮萃取物能增加体细胞的抗氧化力。
实施例4
菠萝果皮萃取物提升细胞抗氧化力
为验证菠萝果皮萃取物对皮肤细胞中氧化压力的调节作用,利用荧光探针DCFH-DA配合流式细胞仪(flow cytometry;Beckman),测定人类皮肤纤维母细胞CCD-966SK以实施例1所述菠萝果皮萃取物处理后,其在氧化刺激下的活性氧物质含量变化。简言之,将2×105个CCD-966SK细胞接种于6孔培养盘,各孔含有2mL MEM细胞培养基。在37℃培养细胞24小时后,移除该培养基,并于37℃以2mL含有或不含1mg/mL菠萝果皮萃取物的MEM细胞培养基处理细胞1小时,再以5μg/mL DCFH-DA溶液处理细胞15分钟。其后,于37℃以有无过氧化氢的下列方式处理各孔细胞:(a)未经菠萝果皮萃取物处理的细胞在无过氧化氢刺激下培养1小时(空白对照组);(b)未经菠萝果皮萃取物处理的细胞以1mM过氧化氢处理1小时(负控制组);或(c)经菠萝果皮萃取物处理的细胞以1mM过氧化氢处理1小时(实验组)。其后,各组细胞以PBS溶液清洗二次,于暗处以200μL胰蛋白酶处理5分钟,再藉由离心(400xg,10分钟)收集得各别细胞沉淀物。该细胞沉淀物以PBS溶液清洗一次及再次悬浮,并使用流式细胞仪侦测细胞的荧光强度(二重复试验)。进行荧光侦测的激发波长为450-490nm,侦测波长为510-550nm。由于DCFH-DA进入细胞后会先被水解为DCFH(二氯二氢荧光素),再被活性氧物质氧化为可发出绿色荧光的DCF(二氯荧光素),经DCFH-DA处理的细胞的荧光强度可反映细胞内活性氧物质含量。
图5显示皮肤纤维母细胞经不同处理后的活性氧物质相对含量(%),以负控制组细胞的活性氧物质含量界定为100%;图中***表示相比负控制组为p<0.001。依据图5,负控制组相比空白对照组呈现明显较高的活性氧物质含量,显示过氧化氢刺激会导致细胞内活性氧物质的累积。然而,相比负控制组,菠萝果皮萃取物的处理使细胞内活性氧物质降低约45%,显示菠萝果皮萃取物本身能清除自由基或提高个体细胞清除自由基的能力。
实施例5
菠萝果皮萃取物抑制黑色素生成
为检视菠萝果皮萃取物对黑色素生成的影响,测定黑色素瘤细胞株B16F10以实施例1所述菠萝果皮萃取物处理后的黑色素含量变化。简言之,将B16F10细胞依1.5×105细胞/孔接种于6孔培养盘,各孔含有3mL DMEM细胞培养基。在37℃培养细胞24小时后,移除该培养基,并以含有0.625mg/mL菠萝果皮萃取物的3mL DMEM细胞培养基处理各孔细胞(实验组)。另设置一对照组,是仅以3mL DMEM细胞培养基处理细胞。在37℃下培养48小时后,收集前述各组细胞以测定黑色素含量(三重复试验)。
图6显示黑色素瘤细胞经不同处理后的黑色素相对含量,其数值表示为相对于对照组的黑色素含量的百分比;图中**表示相比对照组为p<0.01。依据该图,相比对照组,菠萝果皮萃取物的处理使黑色含量显着降低约15%,说明菠萝果皮萃取物具有抑制黑色素生成的效果。
实施例6
菠萝果皮萃取物对皮肤含水量、光泽、及毛孔的影响
为评估菠萝果皮萃取物对皮肤含水量、光泽、及毛孔的影响,六位25至40岁的受试者,于检测前先清洁脸部,并待肌肤平衡稳定后,在左、右半脸各别施用添加一基底精华液的面膜,或添加1%(w/w)实施例1所述菠萝果皮萃取物及该基底精华液的面膜,其中该基底精华液包含水、馨鲜酮、己二醇、1,3丁二醇、三仙胶、增稠剂、及三乙醇胺。于施用15分钟后卸下面膜,以按摩方式促进有效成分吸收,再检测施用前后受试者皮肤的含水量、光泽及毛孔数量。
图7显示受试者的平均皮肤含水量变化;图8显示受试者的平均皮肤光泽度变化;图9显示受试者皮肤的平均毛孔数量变化;图中百分比各别表示相对于施用前的皮肤含水量、皮肤光泽度及毛孔数量;图中**表示相比于施用面膜前的数据为p<0.01。依据图7-9,相比施用前,施用菠萝果皮萃取物面膜能显着增加皮肤含水量约20.3%,显着提升皮肤光泽度约13.1%,及有效减少皮肤毛孔数量约10.3%。该些结果说明该添加菠萝果皮萃取物的面膜可改善肤质,包括提升皮肤含水量与光泽及减少毛孔。
综上所述,本发明揭露菠萝果皮萃取物具有抑制黑色素生成及改善肤质的功效,包括提升皮肤含水量与光泽及减少毛孔。该菠萝果皮萃取物亦能提升包含皮肤细胞的多种细胞的抗氧化力,藉此减少个体或皮肤的氧化伤害。因此,该菠萝果皮萃取物可用于制备在皮肤抑制黑色素生成、增加含水量、提升光泽、及减少毛孔的组合物,或制备提升细胞抗氧化力的组合物。该组合物可具有粉末、颗粒、溶液、胶体或膏体的形式,且可制成医药品、食品、饮品、或营养补充剂,藉由口服、局部施用于皮肤或其他方式给予一个体。
Claims (4)
1.一种菠萝萃取物用于制备在皮肤抑制黑色素生成、增加含水量、提升光泽、及减少毛孔的医药组合物的用途,其中所述菠萝萃取物是以溶剂萃取菠萝果皮而获得。
2.根据权利要求1所述的用途,其特征在于,所述溶剂与所述菠萝果皮的重量比范围为20:1至1:1。
3.根据权利要求1或2所述的用途,其特征在于,所述溶剂为水。
4.根据权利要求1所述的用途,其特征在于,所述萃取是在50℃至100℃进行。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962886653P | 2019-08-14 | 2019-08-14 | |
US62/886,653 | 2019-08-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112386547A CN112386547A (zh) | 2021-02-23 |
CN112386547B true CN112386547B (zh) | 2022-10-21 |
Family
ID=74568703
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911411765.3A Active CN112386547B (zh) | 2019-08-14 | 2019-12-31 | 菠萝萃取物的皮肤保健用途 |
CN202010820580.4A Active CN112391307B (zh) | 2019-08-14 | 2020-08-14 | 乳酸片球菌菌株tci188及其用于口腔保健的用途 |
CN202010820593.1A Active CN112385846B (zh) | 2019-08-14 | 2020-08-14 | 凝结芽孢杆菌用于制备解酒的组合物的用途及食用产品 |
CN202010820586.1A Pending CN112386619A (zh) | 2019-08-14 | 2020-08-14 | 沙棘汁液的用途 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010820580.4A Active CN112391307B (zh) | 2019-08-14 | 2020-08-14 | 乳酸片球菌菌株tci188及其用于口腔保健的用途 |
CN202010820593.1A Active CN112385846B (zh) | 2019-08-14 | 2020-08-14 | 凝结芽孢杆菌用于制备解酒的组合物的用途及食用产品 |
CN202010820586.1A Pending CN112386619A (zh) | 2019-08-14 | 2020-08-14 | 沙棘汁液的用途 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11406673B2 (zh) |
CN (4) | CN112386547B (zh) |
TW (4) | TWI734331B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114107121B (zh) * | 2021-12-06 | 2023-03-21 | 华中农业大学 | 一种凝结芽孢杆菌及其在酒精性肝病的治疗中的应用 |
CN116731896A (zh) * | 2022-12-26 | 2023-09-12 | 南京财经大学 | 一株可降解乙醇的凝结芽孢杆菌及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1183839C (zh) * | 2001-09-28 | 2005-01-12 | 陈廷伟 | 含脱氢酶解酒防醉保肝饮料 |
AU2009271287A1 (en) * | 2008-06-24 | 2010-01-21 | Wm. Wrigley Jr. Company | Probiotic chewing gum method of manufacture |
JP5714869B2 (ja) * | 2010-10-29 | 2015-05-07 | 丸善製薬株式会社 | 糖不含有パイナップル抽出物、及びその製造方法、並びにその用途 |
EP2879511B1 (en) * | 2012-08-03 | 2022-08-24 | DuPont Nutrition Biosciences ApS | Feed additive composition |
CN103911326B (zh) * | 2014-03-28 | 2016-08-10 | 内蒙古和美科盛生物技术有限公司 | 凝结芽孢杆菌益生菌制剂的制备 |
CN104017847A (zh) * | 2014-05-05 | 2014-09-03 | 浙江省农业科学院 | 一种芽孢杆菌发酵糖渣原料制备蛋白多肽的方法 |
CN105769702B (zh) * | 2016-04-19 | 2019-06-21 | 广州市暨生元生物科技有限公司 | 一种含菠萝蛋白酶的面膜及其制作方法 |
CN106955256B (zh) * | 2017-03-28 | 2020-03-06 | 海南师范大学 | 一种菠萝酵素的制备方法及其在美白剂中的应用 |
CN106667894B (zh) * | 2017-03-28 | 2019-07-19 | 海南师范大学 | 一种菠萝酵素及其作为酪氨酸酶抑制剂的应用 |
CN106924141B (zh) * | 2017-03-28 | 2020-06-23 | 海南师范大学 | 一种应用于美白领域的菠萝叶提取物的制备方法 |
CN108094792A (zh) * | 2017-12-27 | 2018-06-01 | 天津科技大学 | 一种改善男性亚健康的益生菌发酵功能食品及其制备方法 |
TWI669124B (zh) | 2018-08-09 | 2019-08-21 | 大江生醫股份有限公司 | 芽孢乳酸菌用於製備代謝重金屬及保護肝臟醫藥組成物之用途 |
CN109007676A (zh) * | 2018-08-17 | 2018-12-18 | 江苏新申奥生物科技有限公司 | 一种含乙醛脱氢酶的乳酸菌冻干粉及其制备方法 |
CN111109359B (zh) * | 2019-12-29 | 2022-09-02 | 江南大学 | 多功能乳酸片球菌ccfm1105、其发酵食品及应用 |
-
2019
- 2019-12-31 TW TW108148714A patent/TWI734331B/zh active
- 2019-12-31 CN CN201911411765.3A patent/CN112386547B/zh active Active
-
2020
- 2020-08-14 TW TW109127839A patent/TW202106321A/zh unknown
- 2020-08-14 TW TW109127834A patent/TWI749711B/zh active
- 2020-08-14 CN CN202010820580.4A patent/CN112391307B/zh active Active
- 2020-08-14 CN CN202010820593.1A patent/CN112385846B/zh active Active
- 2020-08-14 CN CN202010820586.1A patent/CN112386619A/zh active Pending
- 2020-08-14 US US16/993,284 patent/US11406673B2/en active Active
- 2020-08-14 TW TW109127835A patent/TWI749712B/zh active
Also Published As
Publication number | Publication date |
---|---|
TW202106321A (zh) | 2021-02-16 |
CN112385846B (zh) | 2024-01-05 |
TW202106285A (zh) | 2021-02-16 |
CN112386619A (zh) | 2021-02-23 |
TW202106317A (zh) | 2021-02-16 |
TW202106868A (zh) | 2021-02-16 |
US20210046126A1 (en) | 2021-02-18 |
US11406673B2 (en) | 2022-08-09 |
TWI749711B (zh) | 2021-12-11 |
CN112391307A (zh) | 2021-02-23 |
CN112386547A (zh) | 2021-02-23 |
CN112391307B (zh) | 2022-08-16 |
TWI734331B (zh) | 2021-07-21 |
CN112385846A (zh) | 2021-02-23 |
TWI749712B (zh) | 2021-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20100135871A (ko) | 섬유모세포의 증식 및/또는 활성을 자극하는 활성 성분 | |
KR20080001791A (ko) | 연교추출물을 함유하는 피부 주름개선용 화장료 조성물 | |
KR102110081B1 (ko) | 복합 효소를 이용한 혼합 추출물을 함유하는 모공 수축 및 항산화용 화장료 조성물 | |
CN112386547B (zh) | 菠萝萃取物的皮肤保健用途 | |
US11213472B2 (en) | VEGFC production promoter | |
KR20070074786A (ko) | 거대배아미 추출물을 함유하는 화장료 조성물 | |
KR101026879B1 (ko) | 피부주름개선용 화장료 조성물의 제조방법 | |
KR101081910B1 (ko) | 키위 추출물을 함유하는 피부톤 개선 및 피부노화방지 효과가 있는 화장료 조성물 | |
KR20170076147A (ko) | 피부 개선용 조성물 | |
KR101854446B1 (ko) | 상동나무 추출물과 미세침을 함유하는 화장료 조성물 | |
KR20100021755A (ko) | 피부 노화 예방 효과를 갖는 피부 화장료 조성물 | |
KR102350857B1 (ko) | 국화 및 목련 유성온천수 추출물의 유산균 발효물을 함유하는 화장료 조성물 및 그 제조방법 | |
CN112237284A (zh) | 野樱莓汁液用于抑止肌肤老化的用途 | |
KR20210144725A (ko) | 항노화제, 항산화제, 항염증제 및 미백제, 그리고 화장료 | |
KR102011654B1 (ko) | 굴, 멍게, 해삼, 군소 및 코고동을 포함하는 기능성 화장료 조성물 | |
KR101995557B1 (ko) | 수련 발효 추출물을 함유하는 화장료 조성물 및 이의 제조방법 | |
KR20200098153A (ko) | 황칠나무 및 자색고구마 추출발효물을 유효성분으로 함유하는 피부 주름 또는 피부 광노화의 예방 또는 개선용 조성물 | |
KR101208013B1 (ko) | 참바늘버섯 균사체 추출물을 함유하는 피부 외용제 조성물 | |
KR101073107B1 (ko) | 베리 칵테일 조성물을 함유하는 화장료의 제조방법 | |
KR20090097550A (ko) | 슈잔드린 및 이 추출물을 유효성분으로 함유하는 화장료조성물 | |
KR102689835B1 (ko) | 벼 발효물 유래 화합물을 포함하는 화장료 조성물 | |
CN112618404A (zh) | 檀香多肽在制备护肤品中的应用及其组合物 | |
KR101441190B1 (ko) | 비양나무 추출물을 포함하는 화장료 조성물 | |
KR101317433B1 (ko) | 지구자, 길경, 밀싹 및 세이지 추출물을 함유하는 미백 화장용 조성물 | |
KR20050110148A (ko) | 싸리나무 및/또는 까마중 추출물을 주요 활성성분으로함유하는 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |